| Date | Title | Description | Source |
| 09.02.2023 | First Prescription for COSELA® (trilaciclib) Issued in China... | - COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital ... | en.prnasia... |
| 08.02.2022 | Congruence Therapeutics Inc. Announces US$50 million Series ... | Congruence Therapeutics, a biotechnology company working at the interface of computational and exper... | lumiravent... |
| 16.12.2021 | G1 Therapeutics : Announces Expansion of COSELA (Trilacicli... | G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
- G1 and Boehringer Ingelhe... | marketscre... |
| 03.11.2021 | G1 Therapeutics Provides Third Quarter 2021 Financial Result... | G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
- Achieved ... | marketscre... |
| 01.10.2021 | G1 Therapeutics : Announces Permanent J-Code from Centers fo... | RESEARCH TRIANGLE PARK, North Carolina, Oct. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nas... | marketscre... |
| 16.09.2021 | G1 THERAPEUTICS : ANNOUNCES NEW SUPPLEMENTAL COSELA (TRILACI... | RESEARCH TRIANGLE PARK, N.C. - G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology com... | marketscre... |
| 15.09.2021 | G1 Therapeutics : Announces New Supplemental COSELA™ (Trilac... | RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX... | marketscre... |
| 15.09.2021 | G1 Therapeutics : Announces New Supplemental COSELA (Trilac... | G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
- New G1 Sales Force to... | marketscre... |
| 26.04.2021 | G1 Therapeutics Announces Publication of Pooled Results from... | – Pivotal Program Evaluated the Effects of Administering COSELA Prior to Chemotherapy on Clinically ... | lumiravent... |
| 21.04.2021 | Rhythm Therapeutics, Inc. Awarded $3.67 million NIH SBIR Fas... | Rishi Arora, MD, FHRS, FAHA “AF is the most common heart rhythm disorder, affecting six million peop... | prweb.com/... |
| 10.12.2020 | Lumira co-leads $12.8 Million raise in Cyrano Therapeutics | Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal th... | lumiravent... |
| 17.08.2020 | G1 Therapeutics Announces Acceptance and Priority Review of ... | – PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration
– Priority Re... | lumiravent... |
| 13.03.2020 | G1 Therapeutics Strengthens Executive Team & Board of Di... | RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-sta... | lumiravent... |
| 26.02.2020 | G1 Therapeutics Provides Q4 & Fiscal Year 2019 Update | RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-sta... | lumiravent... |
| 15.01.2020 | G1 Therapeutics & Quantum Leap Healthcare Collaborate in... | SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — Quantum Leap Healthcare Collaborat... | lumiravent... |
| 11.12.2019 | G1 Therapeutics Presents Additional Efficacy Data from Clini... | RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX)... | lumiravent... |
| 30.09.2019 | G1 Therapeutics presents data from Phase 2 mTNBC trial for t... | RESEARCH TRIANGLE PARK, N.C. and BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics... | lumiravent... |
| 08.08.2019 | FDA Grants G1 Therapeutics Breakthrough Therapy Designation ... | Related Article: G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update | lumiravent... |
| 30.07.2019 | Former Pfizer VP Joins G1 Therapeutics as Chief Business Off... | Related Article: G1 Therapeutics Appoints Garry Nicholson to Chair of the Board of Directors | lumiravent... |
| 18.06.2019 | Phase 2 Trial Data Demonstrates Longer Survival Rates for Wo... | – Detailed data from this trial will be presented at a medical meeting later this year – | lumiravent... |
| 13.06.2019 | G1 Therapeutics Appoints Garry Nicholson to Chair of the Boa... | – Garry Nicholson to serve as new board chair –
– Sir Andrew Witty, Fredric Eshelman, Pharm.D. and p... | lumiravent... |
| 01.06.2019 | New Patient-Reported Outcomes Data Shows Trilaciclib Improve... | G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today presented additional ... | lumiravent... |
| 30.04.2019 | G1 Therapeutics Announces Positive Feedback from Trilaciclib... | Research Triangle Park, N.C., April 29, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX)... | lumiravent... |
| 12.03.2018 | G1 Therapeutics Announces Closing of Offering of Common Stoc... | RESEARCH TRIANGLE PARK, N.C., March 12, 2018 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX),... | lumiravent... |
| 18.05.2017 | Term Sheet — Thursday, May 18 | DOING THEIR OWN THING
It’s fairly normal for successful venture capital pros to spend their careers ... | fortune.co... |
| 17.05.2017 | Term Sheet — Wednesday, May 17 | VALUE ADD, AMAZON, CYBER-CORN
In which Mark Cuban trolls venture capitalists: At the Lerer Ventures ... | fortune.co... |
| 09.05.2017 | Term Sheet — Tuesday, May 9 | PROFITABILITY OVER PASSION
Land of Opportunity: Yesterday’s Term Sheet included a link to this story... | fortune.co... |
| 17.04.2017 | Term Sheet — Monday, April 17 | EXUBERANT DEALMAKING
Good morning!
Paid Content You can't secure what you can't see From ExtraHop
Bu... | fortune.co... |
| 12.05.2016 | G1 Therapeutics Completes $47M Series C Funding | G1 Therapeutics, Inc., a Research Triangle Park, NC-based clinical-stage oncology company, completed... | finsmes.co... |
| 11.05.2016 | G1 Therapeutics Secures $47 Million Series C Financing | G1 Therapeutics Secures $47 Million Series C Financing | lumiravent... |
| 26.02.2016 | Chromis Therapeutics Inc. Raises $3 Million in Seed Round | Chromis Therapeutics Inc., an antiviral drug discovery company in San Diego, has raised $3 million i... | sdbj.com/n... |
| 05.02.2015 | G1 Therapeutics Raises $33 Million in Series B Financing | G1 Therapeutics Raises $33 Million in Series B Financing | lumiravent... |
| 16.10.2013 | G1 Therapeutics Raises $12.5M in Series A Financing | G1 Therapeutics, Inc., Chapel Hill, NC-based pharmaceutical company that focuses on the discovery an... | finsmes.co... |
| 16.10.2013 | G1 Therapeutics Raises $12.5M in Series A |
CHAPEL HILL, NC, G1 Therapeutics announced that it has raised a Series A financing of $12.5M.
>... | vcnewsdail... |
| 01.05.2013 | G1 Therapeutics developing treatment to protect soldiers, ch... | The team is working on two formulations of the same molecule. The lead formulation is in intravenous... | medcitynew... |
| 07.01.2013 | $125M early stage fund seeks to invest in health startups in... | The HVP IV fund also established a HVP IV SBIC, which is the first licensee of the U.S. Small Busine... | medcitynew... |
| 16.10.2012 | Seed round will help radiation therapy startup prevent harmf... | Jay Strum, president of G1 Therapeutics (formerly G-Zero Therapeutics), said the company’s seed roun... | medcitynew... |
| - | Halozyme Therapeutics, Inc. Announces Proposed Offering of $... | SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme&... | oaoa.com/n... |
| - | Seed round will help radiation therapy startup prevent harmf... | One of the most common and most disruptive drawbacks of existing cancer chemotherapies is the toxic ... | medcitynew... |
| - | Halozyme Therapeutics, Inc. Announces Pricing of Private Off... | SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme&... | oaoa.com/n... |
| - | G1 Therapeutics developing treatment to protect soldiers, ch... | After the Boston Marathon bombing, it’s easy to understand why the government is giving G1 Therapeut... | medcitynew... |
| - | $125M early stage fund seeks to invest in health startups in... | Hatteras Venture Partners announced Monday that the company has closed its fourth fund totaling $125... | medcitynew... |
